智通财经APP获悉，开拓药业-B(09939)午后涨超24%，截至发稿，涨23.38%，报3.8港元，成交额2902.72万港元。
消息面上，近日，开拓药业在投资平台表示，其自主研发的外用雄激素受体（AR）拮抗剂KX-826，1.0%酊剂治疗男性雄激素性脱发（AGA）的Ⅲ期临床顶线数据，将于2026年3月中下旬正式披露。
软库中华此前发布研报称，KX-826对标的全球同靶点的Clascoterone 5%溶液的三期临床试验于2025年12月3日宣布取得积极的顶线结果，说明通过阻断AR信号通路以达到治疗AGA目的的作用机理经过验证，有望成为近30年AGA治疗领域机制突破。该行指出，KX-826具有国内FIC潜力，关键数据结果公布、成功商业化或海外地区商业化许可授权将成为公司估值催化剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.